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Neural epidermal growth factor-like like (NELL) 1 and 2 constitute a family of
multimeric and multimodular extracellular glycoproteins. Although the osteo-
genic effects of NELL1 and functions of NELL2 in neural development have been
reported, their expression and functions in cancer are largely unknown. In this
study, we examined expression of NELL1 and NELL2 in renal cell carcinoma (RCC)
using clinical specimens and cell lines. We show that, whereas NELL1 and NELL2
proteins are strongly expressed in renal tubules in non-cancerous areas of RCC
specimens, their expression is significantly downregulated in cancerous areas.
Silencing of NELL1 and NELL2 mRNA expression was also detected in RCC cell
lines. Analysis of NELL1/2 promoter methylation status indicated that the CpG
islands in the NELL1 and NELL2 genes are hypermethylated in RCC cell lines.
NELL1 and NELL2 bind to RCC cells, suggesting that these cells express a receptor
for NELL1 and NELL2 that can transduce signals. Furthermore, we found that both
NELL1 and NELL2 inhibit RCC cell migration, and NELL1 further inhibits RCC cell
adhesion. These results suggest that silencing of NELL gene expression by pro-
moter hypermethylation plays roles in RCC progression by affecting cancer cell
behavior.
K idney cancers, including renal cell carcinoma (RCC) andurothelial carcinoma of the renal pelvis and ureter,
account for approximately 3% of all cancer incidences.
Although mortality rates of kidney cancers are stabilizing, the
number of new cases is increasing in the USA.(1) Kidney can-
cers are classified according to their histological type and ori-
gin. Cancers originating from kidney epithelia are called RCC.
The most common subtype is clear cell RCC (CCRCC), which
derives its histological appearance from intracellular accumula-
tions of glycogen and lipid. The risk factors and molecular
mechanisms of renal carcinogenesis have been extensively
studied. Loss of heterozygosity or mutations of the von
Hippel-Lindau (VHL) tumor suppressor gene and the mesen-
chymal–epithelial transition (c-MET) proto-oncogene, which
are responsible for inherited tumor syndromes involving the
kidney, have been found in sporadic RCC.(2,3) Epigenetic inac-
tivation by DNA methylation was shown to cause downregula-
tion of the mRNA expression of RAS-associated domain
family-1A (RASSF1A), a tumor suppressor gene, in RCC.(4,5)
However, the mechanisms of RCC development and progres-
sion remain unclear.
Neural epidermal growth factor-like (Nel) is a multimeric
and multimodular extracellular glycoprotein with significant
structural similarity to thrombospondin-1. Whereas Nel was
originally identified in chickens,(6) two related genes, Nel-like1
(NELL1) and Nel-like2 (NELL2), were subsequently described
in mammals, including humans.(7) Based on sequence similari-
ties, mammalian NELL2 appears to be the ortholog of chicken
Nel. Human NELL1 and NELL2 have approximately 55%
homology at the amino acid level. The human NELL1 and
NELL2 genes were mapped to chromosomes 11p15.1 and
12q12, respectively.
Previous studies showed that NELL1 plays important roles
in osteogenic differentiation.(8,9) NELL1 is overexpressed in
patients with unilateral coronal synostosis,(8) which is a com-
mon form of craniosynostosis. NELL1 also induces bone
regeneration in calvarial defects(10) and in a rat femoral dis-
traction model.(11)
Nel-like2 is predominantly expressed in the nervous system
and has been implicated in neural development.(7,12–14)
Recently, we showed that chicken Nel (NELL2) regulates reti-
nal axon guidance(15) and production of retinal ganglion cells
during development.(16)
Expression of NELL1 and NELL2 genes has been studied in
human lymphoma, in cancers of the central nervous system,
prostate, and bladder, and in cancer cell lines.(17–20) Further-
more, NELL1 and NELL2 expression was reported in adult and
embryonic normal kidney.(6,7,17) However, little is known
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about the expression and functions of NELL1 and NELL2 in
RCC. Here we show that, whereas NELL1 and NELL2 are
strongly expressed in non-cancerous renal tubules, their
expression is downregulated in cancerous areas of CCRCC
specimens and in RCC cell lines. In addition, the CpG islands
in the NELL1 and NELL2 promoter regions are hypermethylat-
ed in RCC cells. In vitro, NELL1 suppresses the migration and
adhesion of RCC cells, and NELL2 suppresses RCC cell
migration. These results suggest that NELL protein expression
is downregulated in RCC, presumably by promoter hyperme-
thylation, and that lack of NELL expression may contribute to
RCC progression by altered regulation of cancer cell behavior.
Materials and Methods
Clinical samples. Formalin-fixed paraffin-embedded CCRCC
tissues were obtained from surgical pathology files (between
2010 and 2012) of the Pathology Section of Kanazawa Univer-
sity Hospital (Kanazawa, Japan). This project was approved by
the research ethics committee on genetic analysis of Kanazawa
University (approval no. 320).
Immunohistochemistry. Four-micron sections of CCRCC
samples were analyzed by immunohistochemistry (IHC) using
anti-NELL1 and anti-NELL2 antibodies (HPA051535, 1 ⁄100
and HPA035715, 1 ⁄300 dilutions; Sigma-Aldrich, St. Louis,
MO, USA) according to the manufacturer’s protocol, except
that antigen retrieval was carried out at 121°C for 15 min. The
LSAB2 kit Universal (Dako, Glostrup, Denmark) was used for
detection. NELL1 and NELL2 expression was scored for both
cancerous and non-cancerous areas on a graded 0 (no expres-
sion) to +3 (very strong expression) scale. Immunohistochem-
istry scores were calculated by subtracting the scores of
cancerous areas from those of adjacent non-cancerous areas.
Therefore, positive IHC scores indicated downregulation of
NELL expression in cancer cells, whereas negative scores indi-
cated upregulation.
Cell lines. Renal cell carcinoma (OS-RC-2, TUHR14TKB,
and VMRC-RCW) and HEK293T cell lines were obtained
from the Riken Cell Bank (Tsukuba, Japan). Renal cell
carcinoma and HEK293T cells were cultured in RPMI and
DMEM, respectively, containing 10% FBS and penicillin
⁄ streptomycin.
Quantitative RT-PCR, methylation-specific PCR, and bisulfide
sequencing PCR. Quantitative RT-PCR (qPCR) was carried out
with first-strand cDNAs of the cell lines and SYBR PremixEx
TaqII (Takara Bio, Otsu, Japan) using the Viia7 system (Life
Technologies, Carlsbad, CA, USA). Unmethylated cytosines in
the genomic DNAs from the cell lines were converted to uracil
by bisulfide reactions using the EZ DNA Methylation-Gold Kit
(ZYMO Research, Irvine, CA, USA). Methylation-specific PCR
(MSP) was carried out using the TaKaRa EpiScope MSP Kit.
Bisulfide sequencing PCR (BSP) was carried out using the bisul-
fide-treated genomic DNAs and EpiTaq HS (Takara). The PCR
products were inserted into the pGEM-T easy vector (Promega
KK, Tokyo, Japan) and transformed into DH5a, and plasmids
isolated from 10 colonies of each sample were sequenced. The
primer sequences and PCR conditions used are shown in
Table 1.
5-Azacytidine treatment of RCC cell lines. The OS-RC-2,
VMRC-RCW, and TUHR14TKB cells were plated in 100-mm
plates on day 0. The cells were treated with 5 lM 5-azacyti-
dine (Sigma-Aldrich) for 5 days. Total RNA extraction, cDNA
synthesis and qPCR were carried out as described above.
Luciferase assay. NELL1 and NELL2 putative promoter
regions were ligated into pCpGL-basic(21) (kindly provided by
Prof. Michael Rehli, University Hospital Regensburg,
Regensburg, Germany). NELL1 and NELL2 transcriptional fac-
tors, RUNX2(22) and E2F1(23) were kindly provided by Prof.
Yoshiaki Ito (National University of Singapore, Singapore)
(pEF-BOS-RUNX2)(24) and Prof. Kristian Helin (University of
Copenhagen, BRIC, Copenhagen, Denmark, E2F1 ⁄pCMV-
HA,(25) Addgene plasmid #24225). RUNX2 was amplified from
pEF-BOS-RUNX2 and inserted into pCMV-HA-N (Takara
Bio). After incubation with ⁄without methyltransferases,
NELL1 ⁄pCpGL and NELL2 ⁄pCpGL were transfected with
their transcriptional factors and pGL 4.74 into HEK293T cells.
The luciferase activity was measured using the Dual-Luciferase
Reporter Assay System (Promega KK).
Preparation of alkaline phosphatase fusion proteins. NELL1
protein fused to an alkaline phosphatase (AP) tag (NELL1-
AP), NELL2-AP, and AP proteins were prepared and purified
as previously described.(26)
Cell migration assay. The cell migration assay was carried out
basically as previously described.(27) The lower side of the Tran-
swell membrane inserts (product #3422; Corning, Corning, NY,
USA) was coated with 40 nM or 400 nM AP, NELL1-AP, or
NELL2-AP protein at 4°C overnight, blocked with 20 mg ⁄mL
BSA in PBS for 3 h at 4°C, and then washed with RPMI-1640.
OS-RC-2 or VMRC-RCW cells (1 9 105 cells) were dissociated
with 1 mM EDTA and were seeded inside the Transwell. The
cells were then allowed to migrate to the lower side of the mem-
brane in RPMI-1640 with 1% FBS at 37°C overnight, fixed with
4% paraformaldehyde, and then stained with hematoxylin. The
upper side of the membrane was wiped with a cotton swab, and
the cells that had migrated to the lower side of the membrane
were quantified. For each Transwell membrane, at least three










NELL1 Quantitative RT-PCR ATGGCCAGGTGTGGACCTTG TCTGGTGTCACATTCTGGGC 60 40
NELL2 Quantitative RT-PCR CCACTTAAGTCGGCTCTTGC ATGGTCTGGTCCTTGCACTC 60 40
GAPDH Quantitative RT-PCR GTCTCCTCTGACTTCAACAGCG ACCACCCTGTTGCTGTAGCC 60 40
NELL1 MSP-Methyl. GATTTCGATTTCGGTGTTTC CTACGTTCGTCTAAAAACCCG 60 35
NELL2 MSP-Methyl. CGTTTTATTTGGTAGGGGGC TTCCCTACCGAAAACGAAA 60 35
NELL1 MSP-Unmethyl. TGGGATTTTGATTTTGGTGTTTT ACTACATTCATCTAAAAACCCAAAC 55 40
NELL2 MSP-Unmethyl. TTATGTTTTATTTGGTAGGGGGT AATTCCCTACCAAAAACAAAAC 63 35
NELL1 Bisulfite sequencing TTATAGGGGTTTAATAGGAGAGAGG CCTAACTTAAAACCR*CCAAACTTACTAA 55 35
NELL2 Bisulfite sequencing TGTTTTTTGTTGTATGTTGGTTT AAAAAAAAAAACCTCCCCAAAC 55 35
*R(A+G). Methyl., methylated; MSP, methylation-specific PCR; Unmethyl., unmethylated.
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high-power fields were examined under a microscope. Each
experiment was repeated three times.
Cell adhesion assay. Ninety-six-well cell culture plates were
coated with AP, NELL1-AP, or NELL2-AP protein (400 nM
each) at 4°C overnight. After blocking with 10 mg ⁄mL BSA,
the wells were washed twice with PBS, and OS-RC-2 or
VMRC-RCW cells were then plated at a density of 2.5 9 104
cells ⁄well. The cells were cultured at 37°C for 3 h in RPMI-
1640 with 2% FBS, washed twice with PBS, and then fixed
with 4% paraformaldehyde. Cell numbers in three high-power
fields per well were counted using an inverted microscope.
Experiments were repeated under the same conditions at least
three times.
Statistical analysis. For statistical analysis, ANOVA (for IHC
scores with more than three parameters) and Student’s t-test
(for IHC scores with two parameters, and cell migration and
adhesion assays) were used. Supplementary information is
available in Document S1.
Results
NELL1 and NELL2 protein expression is downregulated in
CCRCC. We first examined and compared NELL1 and NELL2
protein expression in cancerous regions and adjacent non-cancer-
ous areas in tissue samples of 64 CCRCC patients. Both NELL1
and NELL2 proteins were abundantly expressed in renal tubules
in non-cancerous regions (Fig. 1). At higher magnification
(Fig. 1e,g), NELL1 and NELL2 proteins were observed to be
localized in granular cytoplasmic patterns, consistent with the
fact that NELL1 and NELL2 are secreted glycoproteins and thus
processed in the secretory pathway. In contrast, NELL1 and
NELL2 expression was significantly lower in cancerous areas
(IHC scores, 1.88 (NELL1) and 2.17 (NELL2); expression grade
of cancerous area ⁄non-cancerous area, 1.05 ⁄2.09 (NELL1,
P < 0.01) and 0.72 ⁄2.93 (NELL2, P < 0.01); Fig. 1h). No sig-
nificant correlations were observed between the degree of NELL
downregulation and clinicopathological parameters, including
sex or age of patients, or vascular involvement or grade of
tumors (Table 2).
Downregulation of NELL1 and NELL2 expression in RCC cell
lines. We next examined and compared NELL1 and NELL2
mRNA and protein expression in RCC cell lines with that in
the HEK293T cell line derived from human embryonic kidney
using qRT-PCR and Western blot. We found by RT-PCR that
NELL1 and NELL2 mRNA expression levels in the cancer cell







Fig. 1. Protein expression of neural epidermal
growth factor-like like 1 (NELL1) and NELL2 in clear
cell renal cell carcinoma (CCRCC) tissues. (a, b, d–g)
Formalin-fixed paraffin-embedded sections of
CCRCC tissues were immunostained with anti-NELL1
(a, d, e) or anti-NELL2 (b, f, g) antibody. Images (d,
e) and (f, g) are higher magnification views of (a)
and (b), respectively. Both NELL1 and NELL2 were
detected in the cytoplasm of renal tubule cells in
non-cancerous (a, b, right side [non-cancerous]),
but not in cancerous areas (a, b, left side [tumor]).
(c) H&E stain. Scale bar = 200 lm (a–c), 100 lm (d–
g). (h) Average NELL1 and NELL2 expression grades
in the cancerous and non-cancerous areas.
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
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(Fig. 2). Consistent with this finding, the Western blot analysis
showed that the protein expression of NELL1 and NELL2 was
decreased in the RCC cells compared to that observed in
HEK293 cells (Fig. S1). The combined results indicate that
NELL1 and NELL2 expression is downregulated in RCC at
both the mRNA and protein levels.
Promoter hypermethylation of NELL1 and NELL2 genes
in RCC. Aberrant DNA hypermethylation of promoter CpG
islands with associated gene silencing plays crucial roles in
tumor progression. Because hypermethylation of the NELL1
50-UTR has been reported in esophageal adenocarcinoma and
colorectal cancer,(28,29) we speculated that the downregulation
of the NELL1 and NELL2 genes observed in RCC may be
caused by promoter hypermethylation in those genes. To test
this hypothesis, the methylation status of putative promoter
CpG islands of NELL1 and NELL2 genes in RCC cell lines
was examined using MSP. NELL1 gene promoter hypermethy-
lation was detected in VMRC-RCW and TUHR14TKB cells.
NELL2 promoter hypermethylation was detected in VMRC-
RCW cells, and weak hypermethylation was observed in OS-
RC-2 cells. No significant methylation was detected in the
NELL1 or NELL2 promoter regions in control HEK293 cells
(Fig. 3).
To further investigate promoter methylation status, we car-
ried out BSP of the CpG islands that included the putative pro-
moter regions of NELL1 (690 to 100) and NELL2 (320 to
+678) in RCC cell lines (Fig. 4). We numbered the CpG
islands in these regions in the 50 to 30 direction (NELL1, Nos.
1–78; NELL2, Nos. 1–86). The analyses of the NELL1 pro-
moter detected CpG island hypermethylation throughout the
analyzed region in VMRC-RCW cells, high methylation of
CpG islands around No. 20 and No. 45 in OS-RC2 cells, and
frequent methylation of CpG islands from No. 1 to No. 30 in
TUHR14TKB cells (Fig. 4b). The analyses of the NELL2 pro-
moter region detected methylation of CpG islands around No.
10 in both OS-RC2 and VMRC-RCW cells (Fig. 4d). The
analyses of the NELL2 promoter region showed methylation
of CpG islands around No. 10 in both the OS-RC2 and
VMRC-RCW cells and around No. 80 in the OS-RC-2 cells
(Fig. 4d). No significant CpG island hypermethylation was
detected at the NELL1/2 promoter regions in the HEK293T
cells.
If the NELL1/2 downregulation observed in RCC cells is
caused by promoter hypermethylation, the expression would be
recovered by CpG demethylation. In order to test this hypothe-
sis, we treated RCC cell lines with 5 lM 5-azacytidine and
examined the effects on the NELL1/2 mRNA expression. As
shown in Figure 4(e), the NELL1 expression was elevated in
VMRC-RCW cells. The NELL1 expression in TUHR14TKB
cells was also significantly increased after 5-azacytidine treat-
ment. The NELL2 expression in OS-RC-2 cells was elevated
by 5-azacytidine treatment (Fig. 4f). A slight increase in
NELL2 expression was observed in VMRC-RCW cells,
although the difference was not statistically significant
(P = 0.071). Whereas the increases of NELL1 and NELL2
expression by 5-azacytidine were statistically significant in
most of the above RCC cell lines, their expression levels
after treatment were still lower than those in HKE293T
(Figs 2,4e,f), suggesting that promoter methylation partially
contributes to the silencing of NELL expression.
In order to confirm the effects of CpG methylation on
NELL1/2 expression, we carried out a luciferase assay using
the putative promoter regions of NELL1 and NELL2. Conse-
quently, reporter constructs containing unmethylated NELL1
and NELL2 promoter regions showed high luciferase activity.
In contrast, the luciferase activity was significantly reduced by
treatment with M.SssI, which methylates all cytosine residues
within the dinucleotide recognition sequence 50-CpG-30. Treat-
ment with HpaII, which methylates the second cytosine residue
in 50-CCGG-30, or HhaI, which methylates the first cytosine
residue in 50-GCGC-30, resulted in partial reduction of the
luciferase activity (Fig. 4g,h).
Table 2. Correlation between neural epidermal growth factor-like like 1 (NELL1) and NELL2 subtraction scores (immunohistochemistry [IHC]









Overall 64 1.88 2.17
Sex
Male 43 1.84 0.71† 2.16 0.93†
Female 21 1.95 2.19
Age, years
<60 26 1.65 0.19† 1.88 0.10†
≥60 38 2.03 2.37
Grade
G1 20 2.10 0.18‡ 2.30 0.46‡
G2 43 1.74 2.09
G3 1 3.00 3.00
Vascular involvement
v0 42 1.86 0.86† 2.19 0.86†
v1 22 1.90 2.14
pT
pT1 47 1.83 0.85§ 2.11 0.69§
pT2 4 2.00 2.50
pT3 13 2.00 2.31
pT4 0
†Student’s t-test was carried out. ‡More than three parameters, however only two parameters had more than three samples. Student’s t-test was
carried out between G1 and G2. §ANOVA was carried out.
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These data indicate that the CpG island of NELL1 and
NELL2 promoter regions is hypermethylated in RCC, and sug-
gest that downregulation of NELL1 and NELL2 expression in
RCC was caused, at least in part, by promoter hypermethyla-
tion.
NELL1 and NELL2 bind to RCC cells. The above data on
NELL1 and NELL2 expression may suggest that downregula-
tion of NELL1 and NELL2 gene expression is involved in the
development of RCC. If that is the case, it is likely that
NELL1 and NELL2 proteins exert their functions by binding
to a cell surface receptor and transducing intracellular signals.
We therefore examined whether NELL proteins can bind to
RCC cell lines using NELL1-AP or NELL2-AP as a probe
(Fig. S2a). We incubated RCC and HEK293T cells with
NELL1-AP or NELL2-AP, and binding was detected using the
AP enzyme reaction.(30) Significant binding activity was
detected in all cell lines tested, including HEK293T cells (Fig.
S2b). These results indicate that NELL1 and NELL2 can bind
to RCC cells, and suggest that NELL1 and NELL2 can be rec-
ognized through a specific receptor expressed on those cells.
Effects of NELL proteins on RCC cell behavior. We previously
showed that chicken Nel (NELL2) can act as an inhibitory
axon guidance molecule and regulate morphology of the
growth cone.(15) As many axon guidance molecules also regu-
late behavior of the cell body, we examined whether NELL
proteins can affect the migration and adhesion of RCC cells.
We first tested the effects of NELL1 and NELL2 on cell
migration by using a transfilter assay system. NELL1-AP sig-
nificantly inhibited the migration of OS-RC-2 and VMRC-
RCW cells in a dose-dependent manner. NELL2-AP also sig-
nificantly inhibited the migration of OS-RC-2, but not that of
VMRC-RCW cells (Fig. 5a–d).
We next examined whether NELL1 or NELL2 proteins
affect cell adhesion using NELL-AP protein-coated dishes.
Significant numbers of OS-RC-2 and VMRC-RCW cells
adhered to the AP-coated control dish. In contrast, the number
of adherent cells on the NELL1-AP substratum was dramati-
cally decreased. NELL2-AP did not affect adhesion of the
RCC cells (Fig. 5e–l). The combined results indicate that
NELL1 and NELL2 can regulate RCC cell behavior.
Discussion
In the present study, we analyzed the expression, genomic
DNA methylation, and functions of NELL1 and NELL2 in
RCC. Immunohistochemical studies of clinical samples showed
that, whereas NELL1 and NELL2 are strongly expressed in
non-cancerous renal tubules, their expression is significantly
downregulated in CCRCC areas (Fig. 1). Consistent with the
results of clinical samples, NELL1 and NELL2 mRNA and pro-
tein expression was also reduced in RCC cell lines compared
with that in HEK293T cells, which are derived from non-can-
cerous kidney (Figs 2,S1).
NELL1 and NELL2 expression has been previously reported
in other cancers using clinical samples and cell lines. For
example, NELL1 gene loss was observed in more than 40% of
Hodgkin’s lymphoma patients.(20) NELL2 mRNA expression is
upregulated in benign prostate hyperplasia and prostate can-
cer.(18) NELL2 is also considered as a candidate biomarker for
bladder cancer.(19) Among nervous system tumors, NELL1 and
NELL2 are predominantly expressed in neuroblastoma cell
lines and are also expressed in medulloblastoma, central neuro-
cytoma, and some astrocytic tumors.(17) A recent study showed
that posterior fossa ependymoma is composed of two molecu-
larly distinct groups, and that NELL2 is the most significant
marker for the group that represents less invasive and less met-
astatic tumors with better prognosis.(31) These results suggest
that NELL may be involved in cancer development.
Our studies of DNA methylation status showed that the CpG
islands in the NELL1 and NELL2 promoters are hypermethylat-
ed in RCC cells, whereas no significant NELL1/2 promoter hy-
permethylation was detected in control HEK293 cells. The
(a)
(b)
Fig. 2. mRNA expression of NELL1 and NELL2 in renal cell carcinoma
cell lines. NELL1 (a) and NELL2 (b) mRNA expression levels in renal cell
carcinoma cell lines OS-RC-2, VMRC-RCW, and TUHR14TKB and control
HEK293T cells were analyzed using quantitative RT-PCR. Expression
levels are quantified as NELL1 or NELL2 ⁄ GAPDH and plotted as
means  SD.
Fig. 3. Methylation-specific PCR analysis of the NELL CpG islands in
renal cell carcinoma cells. Genomic DNA was analyzed by PCR using
specific primers for methylated (Methyl) or unmethylated (Unmethyl)
CpG islands in NELL1 or NELL2 putative promoter regions (NELL1
methylated, NELL1 unmethylated, NELL2 methylated, and NELL2
unmethylated).
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
on behalf of Japanese Cancer Association.
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Fig. 4. Hypermethylation of CpG islands in the putative promoter region of the NELL1 and NELL2 genes. (a, c) CpG islands (vertical bars) in the
putative promoter regions of NELL1 (a) and NELL2 (c) genes are numbered in the 50 to 30 direction (NELL1, Nos. 1–78; NELL2, Nos. 1–86). Positions of
primer sequences for methylation-specific PCR (MSP) and bisulfide sequencing PCR (BSP) are also shown. (b, d) Methylation status of CpG islands. ●,
Methylated CpG islands (methylation detected in more than 8 of 10 clones); ○, unmethylated islands (methylation not detected in any of 10 clones);
M, incompletely methylated CpG islands (methylation detected in one to seven clones). *This nucleotide in HEK293T differed from the registered
sequence in the database. (e, f) NELL1 and NELL2 mRNA expression levels in OS-RC-2, VMRC-RCW and TUHR14TKB cells with ⁄ without 5-azacytidine
treatment. The NELL1, NELL2 and GAPDH mRNA expression levels were measured using quantitative PCR. NELL1 and NELL2 mRNA expression levels
were normalized by that of GAPDH and plotted as the mean  SD. (g, h) Effects of promoter methylation on NELL1 and NELL2 expression. Firefly
luciferase reporter constructs containing putative promoter regions of NELL1 and NELL2 genes (NELL1 ⁄ pCpGL and NELL2 ⁄ pCpGL) were treated with
M.SssI, HpaII, or HhaI methyltransferases and then transfected into HEK293T cells with RUNX2 ⁄ pCMVHA (for NELL1 ⁄ pCpGL) or E2F1 ⁄ pCMVHA (for
NELL2 ⁄ pCpGL) and the Renilla luciferase expression vector pGL 4.74. The ratio of the firefly ⁄ Renilla luciferase activity was plotted as the
mean  SD.
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degree of promoter hypermethylation and effect of 5-azacyti-
dine treatment varied between RCC cell lines. In the RCC cell
lines in which promoter hypermethylation was particularly
prominent (NELL1 in VMRC-RCW and TUHR14TKB cells,
NELL2 in OS-RC-2 cells), the NELL mRNA expression was
significantly recovered by 5-azacytidine treatment (Fig. 4e,f).
In contrast, recovery of NELL2 expression was not statisti-
cally significant in VMRC-RCW and TUHR14TKB cells.
Interestingly, CpG islands around No. 80 in the NELL2 pro-
moter were methylated only in OS-RC-2, but not in VMRC-
RCW or TUHR14TKB cells (Fig. 4d). In addition, NELL2
expression levels without treatment were much lower in OS-
RC-2 cells than those in VMRC-RCW or TUHR14TKB cells.
These results suggest that CpG methylation around No. 80
may be important for NELL2 downregulation, although it is
plausible that other factors are also involved in NELL2 down-
regulation in OS-RC-2 cells, because the NELL2 expression
level restored by 5-azacytidine treatment was still lower than
those in untreated VMRC-RCW, TUHR14TKB, and
HEK293T cells.
DNA methylation of gene promoters is an important
mechanism of transcriptional downregulation of gene
expression. In cancer cells, many tumor suppressor genes have
been shown to be silenced by promoter hypermethyla-
tion, including p16 ⁄CDKN2 ⁄MTS1,(32) retinoblastoma gene,(33)
and EphA7.(34) In RCC, transcriptional silencing by promoter
hypermethylation was reported for several tumor-suppressor
genes, including VHL(35) and RASSF1A,(36) and differentially
expressed in adenocarcinoma of the lung (DAL-1/4.1B).(37)




Fig. 5. Effect of neural epidermal growth factor-like like 1 (NELL1) and NELL2 on renal cell carcinoma cell migration and adhesion. (a–d) Trans-
filter cell migration assay. The bottom side of the Transwell filter was coated with 40 nM or 400 nM alkaline phosphatase (AP), NELL1-AP or
NELL2-AP. OS-RC-2 (a) or VMRC-RCW (b) cells were placed inside the Transwell chamber and allowed to migrate to the bottom side of the filter
overnight. The cells that migrated to the bottom side of the filter were stained with hematoxylin and photographed. (c, d) Quantification of cell
migration. The numbers of cells that migrated to the bottom side of the filter were plotted as mean  SD. (e–l) Cell adhesion assay. OS-RC-2 (left
three wells of e, and f, h, j) and VMRC-RCW (right three wells of e, and g, i, k) cells were seeded on AP (e, f, g), NELL1-AP (e, h, i), or NELL2-AP
(e, j, k) coated dishes (400 nM each). Low (e) and high (f–k) power views after cell adhesion assay. Adherent cells were stained with hematoxylin.
Adherent cell numbers were quantified and plotted as means  SD (l). HPF, high-power field.
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
on behalf of Japanese Cancer Association.
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100 kidney cancers showed hypermethylation of promoter
DNA in 93% of kidney tumor cases, approximately two-thirds
of which have two or more hypermethylated genes.(38)
Promoter hypermethylation and silencing of the NELL1 gene
were detected in approximately 44% of colorectal carcino-
mas.(29) In esophageal cancer, methylation levels of the NELL1
gene are significantly higher in Barrett’s metaplasia, dysplasia
in Barrett’s esophagus, and esophageal adenocarcinoma than
those in normal esophagus, and inversely correlate with patient
survival rates. These findings indicate that promoter hyperme-
thylation of NELL1 is a common event that occurs at early
stages of Barrett’s-associated esophageal cancer progression
and is a potential biomarker of poor prognosis in early stage
esophageal adenocarcinoma.(28)
In vitro assays of cell behavior in the present study indicated
that both NELL1 and NELL2 inhibit RCC cell migration and
that NELL1 further inhibits RCC cell adhesion. As regulation
of cell migration and adhesion plays crucial roles in cancer
invasion and metastasis, these results raise the possibility that
loss of NELL expression in RCC is involved in cancer pro-
gression. Although no significant correlation was found
between NELL expression levels and the size or extent of the
primary tumor (pT stages), our data show that hypermethyla-
tion and downregulation of the NELL genes already occurs at
early stages of RCC progression. These findings are consistent
with esophageal cancer data,(28) and suggest that decreased
NELL expression plays roles in early oncogenesis.
Our results showing that NELL1 and NELL2 bind to RCC
cells suggest that these molecules regulate the behavior of can-
cer cells by binding to a cell surface receptor and transducing
intracellular signals. We also previously reported that chicken
Nel (NELL2) can bind to and regulate the behavior of retinal
axons.(15) Although no receptors have been identified for
NELL2, recent studies have shown that integrins (b1(39) and
a3b1(40)) act as cell surface receptors for NELL1. Binding of
NELL1 to these integrins promotes adhesion of several
different types of cells, including bone marrow stromal cells,
multipotential mesenchymal cells, chondroprogenitor cells,
pre-osteoblasts, and human osteocarcinoma cells.(39,40) As it is
likely that NELL1 protein interacts with a variety of receptors
through its different domains, the opposite effects of NELL1
on cell adhesion may be mediated by different NELL1 recep-
tors that interact with different domains of NELL1. Further
studies, especially regarding identification of additional recep-
tors and signaling pathways, are required to fully understand
NELL functions in cancer cell behavior regulation.
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Fig. S2. Binding activity of neural epidermal growth factor-like like protein fused to an alkaline phosphatase tag (NELL-AP) to renal cell carci-
noma cells.
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